



Vaccine-Induced Anti-tumor Immunity

Guest Editors:

Prof. Dr. Haihong Zhang

College of Life Sciences, Jilin
University, Changchun, China

Prof. Dr. Xianghui Yu

School of Life Science, Jilin
University, Changchun, China

Prof. Dr. Yongge Wu

National Engineering Laboratory
for AIDS Vaccine, School of Life
Sciences, Jilin University,
Changchun 130012, China

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

Dear Colleagues,

Cancer is one of the leading causes of death worldwide and represents a significant public health challenge. Currently, with the success of immune checkpoint inhibition treatment, research on tumor vaccines, which are an important component of tumor immunotherapy.

In order to better understand and keep up with the latest scientific advancements and development trends in the field of tumor vaccine research, this Special Issue is focused on the recent scientific and technical progress made in this field.

Based on your extensive knowledge and experience, we are pleased to invite you to contribute with original research articles and reviews about cancer vaccines. Research areas may include (but are not limited to) the following:

- The design and development and anti-tumor prophylactic and therapeutic effects of tumor vaccine.
- The mechanisms of the vaccine-induced anti-tumor immune response.
- The modulation of the tumor immune microenvironment using tumor vaccines
- Combination therapy of tumor vaccines with other therapies.
- Recent advances in novel tumor prophylactic and therapeutic vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com